1. Home
  2. SUUN vs ACRV Comparison

SUUN vs ACRV Comparison

Compare SUUN & ACRV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

SUUN

SolarBank Corporation

HOLD

Current Price

$0.70

Market Cap

61.2M

Sector

N/A

ML Signal

HOLD

Logo Acrivon Therapeutics Inc.

ACRV

Acrivon Therapeutics Inc.

HOLD

Current Price

$1.63

Market Cap

47.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SUUN
ACRV
Founded
2013
2018
Country
Canada
United States
Employees
N/A
N/A
Industry
Medicinal Chemicals and Botanical Products
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
61.2M
47.6M
IPO Year
2024
2022

Fundamental Metrics

Financial Performance
Metric
SUUN
ACRV
Price
$0.70
$1.63
Analyst Decision
Strong Buy
Buy
Analyst Count
2
6
Target Price
$5.00
$13.00
AVG Volume (30 Days)
969.5K
852.9K
Earning Date
01-01-0001
04-20-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
13.14
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$112.68
N/A
Revenue Next Year
$1.75
$805.34
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.64
$1.05
52 Week High
$4.75
$5.65

Technical Indicators

Market Signals
Indicator
SUUN
ACRV
Relative Strength Index (RSI) 33.52 47.09
Support Level N/A $1.49
Resistance Level $0.90 $1.86
Average True Range (ATR) 0.07 0.12
MACD 0.01 0.02
Stochastic Oscillator 23.32 46.07

Price Performance

Historical Comparison
SUUN
ACRV

About SUUN SolarBank Corporation

PowerBank Corp is an independent renewable and clean energy project developer, power producer, and asset operator in Canada and the United States, with the majority of its revenue coming from the United States. The Company operates through two reportable segments: Development and EPC, which involves the development and construction of solar photovoltaic power projects, and IPP Production, which includes the operation of solar power and battery energy storage systems. Corporate and other activities cover operation, maintenance, and repairs. The majority of revenue is generated from the Development and EPC segment.

About ACRV Acrivon Therapeutics Inc.

Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.

Share on Social Networks: